Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 10;9:157–170. doi: 10.2147/JHC.S353956

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Huang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Subgroup analyses according to different variables for comparing overall survival between regorafenib combined with sintilimab (rego-sintilimab) and regorafenib. A trend of better survival benefit for rego-sintilimab over regorafenib was observed in all the subgroups. Rego-sintilimab reduced risk of death, with benefit only seen in patients with neutrophil-to-lymphocyte ratio (NLR) ≤ 3.6 (HR, 0.518 [95% CI, 0.257–0.955]), not in those with NLR > 3.6 (0.852 [0.461–1.572]; P = 0.002 for interaction). There was no statistically significant interaction between the treatment method and other subgroups (P > 0.05 for all interactions).

Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group.